Phase 1 study with a single-ascending-dose (SAD) part and a multiple-ascending-dose (MAD) part.

SAD design:

* Five parallel treatment arms, with treatments labeled A, B, C, D, E.
* Three screening and pre-treatment visits, numbered -3, -2, -1.
* Single dose on visit 1 (day 1) at TIME 0.
* ECGs 0, 3, 6, 8, 12, 20, 24, and 48 hours post dose.
* The ECG at 0 hours post dose on visit (and day) 1 is considered the baseline.

MAD design:

* Four parallel treatment arms, with treatments labeled A, B, C, D, which are the same as A, B, C, D in the SAD.
* Three screening and pre-treatment visits, numbered -3, -2, -1.
* Daily doses on days 1 - 14 at time = 0 on each day.
* ECGs at 0 and 6 hours post dose on DAYs 1, 2, 3, 8, 12, 14, and 24 and 168 hours after the 14th dose.
* The ECG at 0 hours post dose on VISIT (and DAY) 1 is considered baseline.

Variables:

* PART: SAD or MAD.
* ID: Subject identifier.
* DAY: Day number as in the source data. See DAY2.
* DAY2: For the SAD part, DAY2 = 1 for the day of and the two days following the dose administration, whereas DAY = 1, 2, 3.
* VISIT: Visit number as in the source data. See VISIT2.
* VISIT2: For the SAD part, VISIT2 = 1 for the day of and the two days following the dose administration, whereas VISIT = 1, 2, 3.
* TIME: Time post dose, in hours, reported in the source data. See TIME2.
* TIME2: For the SAD part, TIME is missing for the screening and pre-treatment visits; TIME2 = 0 then. For the SAD part, TIME is missing for the observation on DAY 3; TIME2 = 48 hours then.
* PARAM: HR for heart rate, or QTCF for QTcF.
* VALIE: Observed value of HR, in beats per minute, or QTcF, in milliseconds.
* BASE: Baseline VALUE.
* CHANGE: Change from baseline for observations after the baseline; missing otherwise.
* TREAT: A, B, C, D, or E.
* AGE: Subject’s age in years.
* SEX: Subject’s sex: M=Male, F=Female.
* RACE: Subject’s race.